Effects of pristane on cytochrome P450 isozyme expression in rat tissues

International Journal of Environmental Research and Public Health

Volumn 2, Issue 1, 2005, Pages 138-146

  Howard, Carolyn B ^a   Samuel, Jacqueline ^a   Henderson, Shalonda B ^a   Stevens, Jacqueline ^a   Thomas, Paul E ^b   Cuchens, Marvin A ^c  

^a Jackson State University   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

3 methylcholanthrene; Cytochrome P450 (CYP); Monoclonal antibodies; Phenobarbital; Pristane; Western blots

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 ISOENZYME; MONOCLONAL ANTIBODY; PRISTANE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; B LYMPHOCYTE ACTIVATION; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; INDUCED MUTATION; LIVER MICROSOME METABOLISM; NONHUMAN; PEYER PATCH; PROTEIN EXPRESSION; RAT; THYMUS; THYMUS LYMPHOMA; TISSUE SPECIFICITY; WESTERN BLOTTING;

EID: 22044435647     PISSN: 16604601     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph2005010138     Document Type: Conference Paper

References (34)

1. Felix, K.; Potter M.; Bornkamm, G. W.; Janz, S.: In vitro mutagenicity of the plasmacytomagenic agent pristane (2, 6, 10, 14-tetramethylpentadecane). Cancer Lett., 1997, 113(1-2), 71-76.
2. Felix, K.; Gerstmeier, S.; Kelliher, K. A.; Bornkamm, G. W., Janz S. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice. Cancer Res. 1999, 59(15), 3621-3626.
3. Potter, M.; Jones, G.; Dubois, W.; Williams, K.; Mushinski, E.: Myeloma proteins that bind Hsp65 (GroEL) are polyreactive and are found in high incidence in pristine induced plasmacytomas. Curr. Top. Microbiol. Immunol., 2000, 252, 265-271.
4. Felix, K.; Gerstmeier, S.; Kyriakopoulos, A.; Howard, O. M.; Dong, H. F.; Eckhaus, M.; Behne, D.; Bornkamm, G. W., Janz, S.: Selenium deficiency abrogates inflammation-dependent plasma cell tumors in mice. Cancer Res. 2004, 64(8), 2910-2917.
5. Potter, M.; Wax, J. S.; Hansen, C. T.; Kenny, J. J.: BALB/c.CBA/N mice carrying the defective Btkxid gene are resistant to pristine-induced plasmacytomagenesis. Internat. Immunol., 1999, 11(7), 1059-1064.
6. Gado, K.; Silva, S.; Paloczi, K.; Domjan, G.; Falus, A.: Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica., 2001, 86(3), 227-236.
7. Harper, C. M.; Soni, M. G.; Mehendale, H. M.; Cuchens, M. A.: Pristane-induced effects on cytochrome P-4501A, ornithine decarboxylase and putrescine in rats. Cancer Lett., 1995, 95 (1-2), 11-21.
8. Garrett, L. R.; Cuchens, M. A.: Pristane induced effects on chromatin of rat lymphoid cells. J. Cell. Biochem., 1991, 45, 311-316.
9. Garrett, L. R.; Randall, C. C.; Cuchens, M. A.: Thymic tumors induced by 3-methylcholanthrene treatment of rat Peyer's patches. Exp. Mol. Pathol., 1991, 54, 47-60.
10. Garrett, L. R.; Jones, C. J.; Cuchens, M. A.: Pristane induced gene activation. Chem-Biol Interact., 1981, 119-130.
11. Banbura, M.; Ackland-Berglund, C.; Lee, S.; Hamernik, D.; Jones, C.: Analysis of transcriptional activation of a cyclic AMP response element by 2, 6, 10, 14-tetramethylpentadecane (pristane) in JB6 mouse epidermal cells. Mol. Carcino. 1994, 11, 204-214.
12. Garrett, L. R.; Ackland-Berglund, C. E.; Jones, C. J.; Cuchens, M. A.: Differential effects of TPA and pristane on gene expression and transformation in mouse epidermal cells. Exp. Cell. Res. 1993, 205, 416-421.
13. Lee, S. H.; Ackland-Berglund, C. E.; Jones, C. J.: The tumor promoter pristane activates transcription by a cAMP dependent mechanism. Mol. Cell Biochem., 1992, 110, 75-81.
14. Castagna, M.: Phorbol esters as signal transducers and tumor promoters. Biol. Cell, 1987, 59, 3-14.
15. Roesch, S. F.; Wiebel, F. J.: Differential effects of 12-O-tetradecanolyphorbol 13-acetate on cytochrome P-450I and suppression of P-450II. Toxicol., 1990, 61, 147-159.
16. Bost, K. L.; Cuchens, M.: The role of Peyer's patches in carcinogenesis. I. The adsorption from the gut and retention of 3-methylcholanthrene by Peyer's patches. Carcinogeno. 1986, 7, 1251-1256.
17. Malins, D. C.; Anderson, K. M.; Gilman, N. K.; Green, V. M.; Barker, E. A.; Hellstrom, K. E.: Development of a cancer DNA phenotype prior to tumor formation. Proc. Natl. Acad. Sci. U SA, 2004, 101(29), 10721-10725.
18. Fujii-Kuriyama, Y.; Imataka, H.; Sogawa, K.; Yasumoto K.; Kikuchi, Y.: Regulation of CYP1A1 expression. FASEB J., 1992, 6, 706-710.
19. Sesardic, D.; Cole, K. J.; Edwards, R. J.; Davies, D. S.; Thomas, P. E.; Levin, W.; Boobis, A. R.: The inducibility and catalytic activity of cytochromes P450s (P450IA1) and P450d (P450IA2) in rat tissues. Biochem. Pharmacol., 1990, 39, 499-506.
20. Zacharova, L.Y.; Gulyaeva, L. F.; Lyakhovich, V. V.; Mikhailova, O. N.; Timofeeva, O. A.; Filipenko, M. L.; Kaledin, V. I.: Cytochrome P4501A1 and 1A2 gene expression in the liver of 3-methylcholanthrene- and o-aminoazotoluene- treated mice: a comparison between PAH-responsive and PAH-nonresponsive strains. Toxicol. Sci., 2003, 73(1), 108-113.
21. Wang, J. S.; Backman, J. T.; Taavitsainen, P.; Neuvonen, P. J.; Kivisto, K. T.: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab. Dispos., 2000, 28(8), 959-965.
22. Yamazaki, H.; Inoue, K., Shaw, P. M.; Checovich, W. J.; Guengerich, F. P.; Shamada, T.: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J. Pharmacol. Exp. Ther. 1997, 283(2), 434-442.
23. Yoo, J. S.; Smith, T. J.; Ning, S. M.: Modulation of the levels of cytochromes P450 in rat liver and lung by dietary lipid. Biochem. Pharmaco., 1992, 43, 2535-2542.
24. Miller, M. S.; Jones, A. B.; Chauhan, D. P.; Park, S. S.; Anderson, L. M.: Induction of cytochrome P-450IA1 in fetal rat liver by a single dose of 3-methylcholanthrene. Biochem. Biophys. Res. Comm., 1991, 176, 280-287.
25. Peng, J. Z.; Remmel, R. P.; Sawchuk, R. J.: Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. Drug Metab. Dispos,, 2004, 32(8), 805-812.
26. Shimada, T.; Sugie, A.; Yamada T.; Kawazoe H.; Hashimoto, M.; Azuma, E.; Nakajima, T.; Inoue, K.; Oda, Y.: Dose-response studies on the induction of liver cytochromes P4501A1 and 1B1 by polycyclic aromatic hydrocarbons in arylhydrocarbon-responsive C57BL/6J mice. Xenobiotica., 2003, 33(9), 957-971.
27. Perloff, M. D.; von Moltke, L. L.; Greenblatt, D. J.: Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica, 2004, 34(2), 133-150.
28. Robottom-Ferreira, A. B.; Aquino, S. R.; Queiroga, R.; Albano, R. M.; Ribeiro Pinto, L. F.: Expression of CYP2A3 mRNA and its regulation by 3-methylcholanthrene, pyrazole, and B-ionone in rat tissues. Braz. J. Med. Biol. Res,, 2003, 36(7), 839-844.
29. Yang, C. S.; Patten, C. J.; Ishizaki, H.; Yoo, J. S. H.: Induction, purification and characterization of cytochrome P450 IIE. Methods in Enzymol., 1990, 206, 595-601.
30. Sueyoshi, T.; Negishi, M.: Phenobarbital response of cytochrome P450 genes and nuclear receptors. Annual Rev. of Pharmacol. and Toxicol. 2001, 41, 123-143.
31. Thomas, P. E.; Reik, L. M.; Ryan, D. E.; Levin, W.: Characterization of nine monoclonal antibodies against rat hepatic cytochrome P450c. Delineation of at least five spatially distinct epitopes. J. Biol. Chem., 1994, 259, 3890-3899.
32. Reik, L. M.; Maines, S. L.; Ryan, D. E.; Levin, W.; Bandiera, S. B.; Thomas, P. E.: A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. J. Immunol. Methods, 1987, 100, 123-130.
33. Dunning, W. F.; Curtis, M. R.: The respective roles of longevity and genetic specificity in the occurrence of spontaneous tumors in hybrids between two inbred lines of rats. Cancer Res., 1946, 6, 61-68.
34. Howard, C. B.; Stevens, J.; Izevbigie, E. B.; Walker, A.; McDaniel, O.: Time and dose-dependent modulation of phase 1 and phase 2 gene expression in response to treatment of MCF-7 cells with a natural anti-cancer agent. Cell. Mol. Biol., 2003, 49, 1057-1065.